<DOC>
	<DOCNO>NCT00638482</DOCNO>
	<brief_summary>Intrarenal calcification ( nephrocalcinosis ) present Dent 's disease likely contribute progression toward renal failure . In order prevent complication usually propose treat affect patient childhood high dos thiazide .</brief_summary>
	<brief_title>Dose-Dependent Effect Thiazide Dent 's Disease Hypercalciuria</brief_title>
	<detailed_description>Intrarenal calcification ( nephrocalcinosis ) present Dent 's disease likely contribute progression toward renal failure . In order prevent complication usually propose treat affect patient childhood high dos thiazide . Indeed , class diuretic use year treat hypertension , low urinary calcium excretion . However dose usually use high , know associated adverse event severe potassium depletion , decrease blood pressure dehydration . The purpose study test whether low dose thiazide would well tolerate , similar efficacy lower urinary calcium excretion , previously demonstrate indication treatment hypertension . Patient recruitment clinical evaluation Eight subject genetically proven Dent 's disease recruit French nationwide network tubulopathies enrol July 2003 December 2005 . All patient meet least three standard criterion disease include hypercalciuria , low molecular weight proteinuria one follow disorder : nephrocalcinosis , nephrolithiasis , renal failure , aminoaciduria , glucosuria , renal phosphate wasting , familial history Dent 's disease . The disease confirm patient direct sequence CLCN5 gene accord Lloyd et al . ( 25 ) Patients present hyponatremia ( &lt; 135 mM ) , hypokalaemia ( &lt; 3.3 mM ) , severe fanconi syndrome , chronic renal failure ( GFR estimate Schwartz formula &lt; 30 mL.min-1.1.73m-2 ) exclude study . The protocol approve `` comité de protection de personnes '' ( Paris , Hôtel Dieu ) subject and/or parent give write informed consent participation study . Sodium restriction test Because renal loss sodium report disease , pharmacological study precede sodium restriction test involve NaCl intake equivalent 0.3 mmol/kg BW ) age-adjusted calcium intake 1200-1500 mg/day , assess tolerance sodium depletion effect calcium excretion . Sodium restriction stop 5 day 24h urinary sodium excretion match theoretical salt intake . Blood urine sample take morning , two hour light calcium-free breakfast 30 minute rest supine position first last day low sodium diet determine electrolyte , plasma protein , hematocrit , plasma renin aldosterone concentration . PHARMACOLOGICAL STUDY After completion sodium restriction test , seven remain patient enter three-period , forced titration sequential open-label trial . They instruct follow normal sodium , isocaloric diet , age-adjusted calcium intake 1200 1500 mg/d . One patient tendency hypokalaemia ( 3.3 mM ) , require potassium chloride salt supplementation enter trial . After one month run-in phase , patient receive sequentially low dose ( 6.25 mg/day ) , intermediate dose ( 12.5 mg/day ) , high dose ( 25 mg/day ) hydrochlorothiazide ( HCTZ ) , dose administered period two month . Amiloride ( 5 mg/day ) start begin study , continue throughout sequential trial reduce risk HCTZ-induced hypokalaemia . For safety reason , two patient receive last 25 mg dose HCTZ body weight ( BW ) &lt; 25 kg . The last HCTZ dose follow one month withdrawal period ( phase E ) . Clinical ( blood pressure BW ) , biological hormonal evaluation conduct baseline end treatment period , 9:00 10:00 hour , two hour light calcium-free breakfast one hour-rest recline position . At end baseline washout period treatment period , two successive 24-h urine collection obtain , morning spot urine sample collect day investigation measurement urine electrolyte ( Na , K , calcium ) creatinine . Hematocrit , electrolyte , creatinine , protein , renin aldosterone concentration measure blood sample . Additionally , Blood Pressure , Body Weight biological tolerance assess 15 day increase HCTZ dose . Analytical method Methods determination plasma sodium , potassium , creatinine , magnesium , PTH , 25-OH vitamin D , renin , aldosterone calcitriol level describe elsewhere . Statistical Methods The effect sodium restriction HCTZ clinical biological marker first evaluate Friedman 's test . If global time-effect significant , change baseline last measurement treatment period test Wilcoxon 's paired test . All data express median range [ minimum ; maximum ] , except otherwise specify . Values 24h-urine collection period use analysis mean measurement make two consecutive daily collection . Values give 24-h collection exclude analysis creatinine excretion collection vary 15 % sodium excretion vary 25 % mean value collection patient . All analysis carry use SAS Statistical Software ( Version 8.2 , Cary , NC , USA ) STATVIEW ( SAS Institute Inc. , Cary NC ) p value le 0.05 consider significant .</detailed_description>
	<mesh_term>Nephrolithiasis</mesh_term>
	<mesh_term>Kidney Calculi</mesh_term>
	<mesh_term>Dent Disease</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Children &gt; 3 yr old meet least three standard criterion Dent 's disease include hypercalciuria , low molecular weight proteinuria one follow disorder : nephrocalcinosis , nephrolithiasis , renal failure , aminoaciduria , glucosuria , renal phosphate wasting , familial history Dent 's disease . Dent 's Disease confirm direct sequencing CLCN5 gene accord Lloyd et al . Patients present hyponatremia ( &lt; 135 mM ) , hypokalaemia ( &lt; 3.3 mM ) , severe fanconi syndrome , chronic renal failure ( GFR estimate Schwartz formula &lt; 30 mL.min1.1.73m2 ) exclude study . Overt renal loss sodium Inability adapt severe sodium restriction</criteria>
	<gender>Male</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2003</verification_date>
	<keyword>Dent 's disease</keyword>
	<keyword>Nephrolithiasis</keyword>
	<keyword>clinical trial</keyword>
	<keyword>thiazide</keyword>
</DOC>